Singapore

News & Events - Singapore Press Release

TeleChem International, Inc. awarded multi-patient genotyping patent in Singapore.

Sunnyvale, CA, October 28, 2005 – On September 30th, TeleChem International, Inc. was awarded a patent for multi-patient genotyping technology from the Intellectual Property Office of Singapore. Wong Sheng Kwai, Acting Registrar of Patents from the Registry of Patents Singapore, signed the Certificate of Grant of Patent, granting TeleChem International patent protection on its invention entitled “Microarray Method of Genotyping Multiple Patients at Multiple Loci”. Earlier this year, the United States Patent and Trademark office issued U.S. patent 6,913,879 on the same invention, but Singapore is the first foreign entity to grant patent protection on TeleChem International’s multi-patient technology. Singapore Patent Number 94899 grants the company patent protection for its methods of genotyping many patients at once. In a preferred embodiment, patient samples are amplified by the polymerase chain reaction, configured into microarrays, hybridized with fluorescent oligonucleotides, and genotyped by reading the microarray signals. Because the patient DNA forms the microarray, as many as 100,000 patients can be genotyped in a single hybridization reaction. Multi-patient technology greatly reduces the cost of patient genotyping compared to traditional “single patient” techniques, and the company is currently offering multi-patient genotyping products and services via its wholly owned subsidiary NGS-ArrayIt, Inc.

Company President Rene’ Schena shared her thoughts on the Singapore patent. “We were delighted to learn of the issuance of our Singapore patent. Together with our U.S. patent, the Singapore patent allows us to begin commercializing genetic screens and tests in Southeast Asia, a very exciting market for us. We see a lot of opportunities in Signapore, a biotechnology hub in Southeast Asia. We appreciate the diligence of the IPOS in evaluating our intellectual property.”

About TeleChem International, Inc.
TeleChem is a privately owned company with products and services provided by three corporate divisions: Life Sciences (ArrayIt®), Chemicals, and Diagnostics (NGS-ArrayIt, Inc.). The Life Sciences division offers a complete line of products and services for the microarray industry, a high-technology sector that uses tiny glass “chips” to decipher the human genome. TeleChem’s patented microarray manufacturing technology (U.S. 6,101,946) and supporting products are used in more than 10,000 company and university laboratories worldwide. The Chemicals division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, and industrial and institutional compounding. The Diagnostics Division (NGS-ArrayIt, Inc.) has recently received landmark patents in the United States (6,913,879) and Singapore (94899) for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. NGS-ArrayIt is offering its patented genotyping and disease diagnostics methods to current and new users in the form of testing kits, services, and technology transfer licenses.

Media Contact
Paul Haje
Director of Public Relations
408-744-1331
Email: paul@ArrayIt.com